Advicenne Secures French Reimbursement for Likozam®, Slashes €6M Debt
Event summary
- Advicenne’s Likozam® (clobazam) granted reimbursement by French social security for drug-resistant epilepsy treatment.
- Price set at €92.24 per 150 ml bottle, ending early access program and AAP rebate mechanism.
- Debt reduced by nearly €6 million via receivable from French government under AAP mechanism.
- Advicenne records €1.4 million reversal of provisions related to early access program.
The big picture
Advicenne’s reimbursement win for Likozam® marks a strategic pivot away from early access constraints, aligning with broader industry shifts toward streamlined reimbursement models. The €6 million debt reduction bolsters financial stability, critical for a company navigating late-stage development of other rare disease treatments. This milestone underscores the value of targeted advocacy in securing payer coverage for niche therapies.
What we're watching
- Revenue Clarity
- How the end of AAP rebate mechanism will simplify Advicenne’s financial reporting and revenue predictability.
- Debt Restructuring
- The pace at which Advicenne can leverage this debt reduction in ongoing restructuring efforts.
- Market Expansion
- Whether Advicenne can replicate this reimbursement success in other European markets.
Related topics